{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:05:46Z","timestamp":1789697146814,"version":"4.0.1"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["31-A-14"],"award-info":[{"award-number":["31-A-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor arising from the gastrointestinal tract. Accurate pathological diagnosis and appropriate treatment for this malignancy require a multidisciplinary approach. In consideration of the differences in clinical practice between Asian and Western countries, the Asian Consensus Guidelines for the Diagnosis and Management of GISTs were published in 2016 by multidisciplinary experts in Asian countries (Japan, Korea, China, and Taiwan). Given the accumulation of new evidence since the previous publication, a multidisciplinary expert panel consisting of pathologists, surgical oncologists, and medical oncologists revised the Asian consensus guidelines. This narrative review provides updated consensus recommendations reflecting available evidence, expert opinion, and current clinical practice for the diagnosis and management of GIST in Asian countries.<\/jats:p>","DOI":"10.1007\/s10120-026-01773-4","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:24:29Z","timestamp":1784114669000},"page":"887-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025)"],"prefix":"10.1007","volume":"29","author":[{"given":"Hidekazu","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chueh-Chuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Kwang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwoon-Yong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Po","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-6317","authenticated-orcid":false,"given":"Toshirou","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346.","journal-title":"Cancer Epidemiol"},{"key":"1773_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.4143\/crt.2016.187","volume":"48","author":"DH Koo","year":"2016","unstructured":"Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, et al. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat. 2016;48:1155\u201366.","journal-title":"Cancer Res Treat"},{"key":"1773_CR3","doi-asserted-by":"crossref","unstructured":"Agaimy A, W\u00fcnsch PH. Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg. 2006;391:322\u20139.","DOI":"10.1007\/s00423-005-0005-5"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s11605-009-0828-4","volume":"13","author":"BK Goh","year":"2009","unstructured":"Goh BK, Chow PK, Kesavan SM, Yap WM, Chung YF, Wong WK. A single-institution experience with eight CD117-positive primary extragastrointestinal stromal tumors: critical appraisal and a comparison with their gastrointestinal counterparts. J Gastrointest Surg. 2009;13:1094\u20138.","journal-title":"J Gastrointest Surg"},{"key":"1773_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.humpath.2006.07.002","volume":"37","author":"K Kawanowa","year":"2006","unstructured":"Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527\u201335.","journal-title":"Hum Pathol"},{"key":"1773_CR6","doi-asserted-by":"crossref","unstructured":"Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33:437\u201346.","DOI":"10.1097\/PAS.0b013e318186b158"},{"key":"1773_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway KA, Kim SY, Lodish M, Nos\u00e9 V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108:314\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1773_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4065\/74.6.543","volume":"74","author":"JA Carney","year":"1999","unstructured":"Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543\u201352.","journal-title":"Mayo Clin Proc"},{"key":"1773_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ags3.12527","volume":"6","author":"H Cho","year":"2022","unstructured":"Cho H, Nishida T, Takahashi T, Masuzawa T, Hirota S. Impact of the KIT\/PDGFRA genotype on prognosis in imatinib-na\u00efve Japanese patients with gastrointestinal stromal tumor. Annal Gastroenterol Surg. 2022;6:241\u20138.","journal-title":"Annals of Gastroenterological Surgery"},{"key":"1773_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/PAP.0000000000000166","volume":"24","author":"GW Charville","year":"2017","unstructured":"Charville GW, Longacre TA. Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine. Adv Anat Pathol. 2017;24:336\u201353.","journal-title":"Adv Anat Pathol"},{"key":"1773_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/path.1487","volume":"202","author":"K Kinoshita","year":"2004","unstructured":"Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol. 2004;202:80\u20135.","journal-title":"J Pathol"},{"key":"1773_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"NP Agaram","year":"2008","unstructured":"Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"1773_CR13","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/modpathol.2013.89","volume":"26","author":"J Lasota","year":"2013","unstructured":"Lasota J, Xi L, Coates T, Dennis R, Evbuomwan MO, Wang ZF, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol. 2013;26:1488\u201391.","journal-title":"Mod Pathol"},{"key":"1773_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/path.4677","volume":"238","author":"M Brenca","year":"2016","unstructured":"Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238:543\u20139.","journal-title":"J Pathol"},{"key":"1773_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors. J Transl Med. 2016;14:339.","journal-title":"J Transl Med"},{"key":"1773_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41379-020-0623-z","volume":"34","author":"MA Atiq","year":"2021","unstructured":"Atiq MA, Davis JL, Hornick JL, Dickson BC, Fletcher CDM, Fletcher JA, et al. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol. 2021;34:95\u2013103.","journal-title":"Mod Pathol"},{"key":"1773_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/PAS.0000000000002202","volume":"48","author":"X Gao","year":"2024","unstructured":"Gao X, Xu S, Zhu P, Lao IW, Yu L, Wang J. Primary NTRK\u2014rearranged spindle cell neoplasm of the gastrointestinal tract: a clinicopathological and molecular analysis of 8 cases. Am J Surg Pathol. 2024;48:623\u201331.","journal-title":"Am J Surg Pathol"},{"key":"1773_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/hupa.2002.123545","volume":"33","author":"CD Fletcher","year":"2002","unstructured":"Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459\u201365.","journal-title":"Hum Pathol"},{"key":"1773_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70\u201383.","journal-title":"Semin Diagn Pathol"},{"key":"1773_CR20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"H Joensuu","year":"2008","unstructured":"Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411\u20139.","journal-title":"Hum Pathol"},{"key":"1773_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ejso.2011.06.005","volume":"37","author":"P Rutkowski","year":"2011","unstructured":"Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour\u2014the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011;37:890\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"1773_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihim\u00e4ki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265\u201374.","journal-title":"Lancet Oncol"},{"key":"1773_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10120-014-0386-7","volume":"18","author":"Y Yanagimoto","year":"2015","unstructured":"Yanagimoto Y, Takahashi T, Muguruma K, Toyokawa T, Kusanagi H, Omori T, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426\u201333.","journal-title":"Gastric Cancer"},{"key":"1773_CR24","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/ijc.34157","volume":"151","author":"YH Bang","year":"2022","unstructured":"Bang YH, Ryu MH, Kim HD, Lee HE, Kang YK. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib. Int J Cancer. 2022;151:1770\u20137.","journal-title":"Int J Cancer"},{"key":"1773_CR25","doi-asserted-by":"publisher","first-page":"e1134","DOI":"10.1093\/oncolo\/oyad168","volume":"28","author":"M Yan","year":"2023","unstructured":"Yan M, Lin J, Shu M, Luo Y, Sun K, Yang S, et al. Diagnosis, treatment, and prognosis of patients with primary familial gastrointestinal stromal tumor: a case report and literature review. Oncologist. 2023;28:e1134\u201341.","journal-title":"Oncologist"},{"key":"1773_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2018.02.014","volume":"76","author":"PN Manley","year":"2018","unstructured":"Manley PN, Abu-Abed S, Kirsch R, Hawrysh A, Perrier N, Feilotter H, et al. Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype. Hum Pathol. 2018;76:52\u20137.","journal-title":"Hum Pathol"},{"key":"1773_CR27","first-page":"1515202","volume":"2016","author":"M Tomatsu","year":"2016","unstructured":"Tomatsu M, Isogaki J, Watanabe T, Yajima K, Okumura T, Yamashita K, et al. Multiple gastric gastrointestinal stromal tumors in a patient with neurofibromatosis type 1. Case Rep Surg. 2016;2016:1515202.","journal-title":"Case Rep Surg"},{"key":"1773_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5858\/arpa.2018-0370-RS","volume":"144","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Chopra S. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med. 2020;144:655\u201360.","journal-title":"Arch Pathol Lab Med"},{"key":"1773_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10147-024-02488-1","volume":"29","author":"S Hirota","year":"2024","unstructured":"Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H, et al. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. Int J Clin Oncol. 2024;29:647\u201380.","journal-title":"Int J Clin Oncol"},{"key":"1773_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51\u20138.","journal-title":"Ann Surg"},{"key":"1773_CR31","doi-asserted-by":"crossref","unstructured":"Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20\u201321 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566\u201378.","DOI":"10.1093\/annonc\/mdi127"},{"key":"1773_CR32","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology, Gastrointestinal Stromal Tumors, Version 1.2025 (April 17, 2025)."},{"key":"1773_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s11605-016-3134-y","volume":"20","author":"TM Coe","year":"2016","unstructured":"Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J Gastrointest Surg. 2016;20:1132\u201340.","journal-title":"J Gastrointest Surg"},{"key":"1773_CR34","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3748\/wjg.v24.i26.2806","volume":"24","author":"K Akahoshi","year":"2018","unstructured":"Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018;24:2806\u201317.","journal-title":"World J Gastroenterol"},{"key":"1773_CR35","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00464-015-4494-1","volume":"30","author":"XC Zhang","year":"2016","unstructured":"Zhang XC, Li QL, Yu YF, Yao LQ, Xu MD, Zhang YQ, et al. Diagnostic efficacy of endoscopic ultrasound-guided needle sampling for upper gastrointestinal subepithelial lesions: a meta-analysis. Surg Endosc. 2016;30:2431\u201341.","journal-title":"Surg Endosc"},{"key":"1773_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4103\/eus.eus_51_20","volume":"9","author":"IM Cazacu","year":"2020","unstructured":"Cazacu IM, Singh BS, Luzuriaga Chavez AA, Koduru P, Ejaz S, Weston BR, et al. EUS and EUS-guided FNA\/core biopsies in the evaluation of subepithelial lesions of the lower gastrointestinal tract: 10-year experience. Endosc Ultrasound. 2020;9:329\u201336.","journal-title":"Endosc Ultrasound"},{"key":"1773_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gie.2019.07.018","volume":"91","author":"A Facciorusso","year":"2020","unstructured":"Facciorusso A, Sunny SP, Del Prete V, Antonino M, Muscatiello N. Comparison between fine-needle biopsy and fine-needle aspiration for EUS-guided sampling of subepithelial lesions: a meta-analysis. Gastrointest Endosc. 2020;91:14-22.e2.","journal-title":"Gastrointest Endosc"},{"key":"1773_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/den.13367","volume":"31","author":"T Osoegawa","year":"2019","unstructured":"Osoegawa T, Minoda Y, Ihara E, Komori K, Aso A, Goto A, et al. Mucosal incision-assisted biopsy versus endoscopic ultrasound-guided fine-needle aspiration with a rapid on-site evaluation for gastric subepithelial lesions: a randomized cross-over study. Dig Endosc. 2019;31:413\u201321.","journal-title":"Dig Endosc"},{"key":"1773_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clinimag.2011.04.002","volume":"36","author":"CH Yeh","year":"2012","unstructured":"Yeh CH, Pan KT, Chu SY, Chen CM, Hsu MY, Hung CF, et al. Safety and efficacy of image-guided percutaneous biopsies in the diagnosis of gastrointestinal stromal tumors. Clin Imaging. 2012;36:19\u201323.","journal-title":"Clin Imaging"},{"key":"1773_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2016.02.021","volume":"59","author":"M Eriksson","year":"2016","unstructured":"Eriksson M, Reichardt P, Sundby Hall K, Sch\u00fctte J, Cameron S, Hohenberger P, et al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour\u2014does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer. 2016;59:128\u201333.","journal-title":"Eur J Cancer"},{"key":"1773_CR41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/01.sla.0000218080.94145.cf","volume":"244","author":"JS Gold","year":"2006","unstructured":"Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176\u201384.","journal-title":"Ann Surg"},{"key":"1773_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/ases.13104","volume":"16","author":"A Fukada","year":"2023","unstructured":"Fukada A, Takahashi T, Kurokawa Y, Asaoka T, Teranishi R, Saito T, et al. Laparoscopic resection for recurrent gastrointestinal stromal tumors and paraganglioma in a patient with Carney-Stratakis syndrome: a case report. Asian J Endosc Surg. 2023;16:90\u20134.","journal-title":"Asian J Endosc Surg"},{"key":"1773_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00464-006-9065-z","volume":"21","author":"J Nishimura","year":"2007","unstructured":"Nishimura J, Nakajima K, Omori T, Takahashi T, Nishitani A, Ito T, et al. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc. 2007;21:875\u20138.","journal-title":"Surg Endosc"},{"key":"1773_CR44","doi-asserted-by":"crossref","unstructured":"Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006;243:738\u201345.","DOI":"10.1097\/01.sla.0000219739.11758.27"},{"key":"1773_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/SLE.0000000000000039","volume":"25","author":"T Takahashi","year":"2015","unstructured":"Takahashi T, Nakajima K, Miyazaki Y, Miyazaki Y, Kurokawa Y, Yamasaki M, et al. Surgical strategy for the gastric gastrointestinal stromal tumors (GISTs) larger than 5 cm: laparoscopic surgery is feasible, safe, and oncologically acceptable. Surg Laparosc Endosc Percutan Tech. 2015;25:114\u20138.","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"key":"1773_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12885-017-3741-3","volume":"17","author":"X Lian","year":"2017","unstructured":"Lian X, Feng F, Guo M, Cai L, Liu Z, Liu S, et al. Meta-analysis comparing laparoscopic versus open resection for gastric gastrointestinal stromal tumors larger than 5 cm. BMC Cancer. 2017;17:760.","journal-title":"BMC Cancer"},{"key":"1773_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4251\/wjgo.v10.i1.48","volume":"10","author":"JX Cui","year":"2018","unstructured":"Cui JX, Gao YH, Xi HQ, Cai AZ, Zhang KC, Li JY, et al. Comparison between laparoscopic and open surgery for large gastrointestinal stromal tumors: a meta-analysis. World J Gastrointest Oncol. 2018;10:48\u201355.","journal-title":"World J Gastrointest Oncol"},{"key":"1773_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/den.12404","volume":"27","author":"N Hiki","year":"2015","unstructured":"Hiki N, Nunobe S, Matsuda T, Hirasawa T, Yamamoto Y, Yamaguchi T. Laparoscopic endoscopic cooperative surgery. Dig Endosc. 2015;27:197\u2013204.","journal-title":"Dig Endosc"},{"key":"1773_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ags3.12238","volume":"3","author":"N Hiki","year":"2019","unstructured":"Hiki N, Nunobe S. Laparoscopic endoscopic cooperative surgery (LECS) for the gastrointestinal tract: Updated indications. Ann Gastroenterol Surg. 2019;3:239\u201346.","journal-title":"Ann Gastroenterol Surg"},{"key":"1773_CR50","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/jgh.13768","volume":"32","author":"Y Meng","year":"2017","unstructured":"Meng Y, Li W, Han L, Zhang Q, Gong W, Cai J, et al. Long-term outcomes of endoscopic submucosal dissection versus laparoscopic resection for gastric stromal tumors less than 2 cm. J Gastroenterol Hepatol. 2017;32:1693\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1773_CR51","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s10620-018-5348-1","volume":"64","author":"EJ Ko","year":"2019","unstructured":"Ko EJ, Bang BW, Kwon KS, Shin YW, Kim HK. Endoscopic enucleation is effective and relatively safe in small gastric subepithelial tumors originating from muscularis propria. Dig Dis Sci. 2019;64:524\u201331.","journal-title":"Dig Dis Sci"},{"key":"1773_CR52","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00464-018-6549-6","volume":"33","author":"B Li","year":"2019","unstructured":"Li B, Chen T, Qi ZP, Yao LQ, Xu MD, Shi Q, et al. Efficacy and safety of endoscopic resection for small submucosal tumors originating from the muscularis propria layer in the gastric fundus. Surg Endosc. 2019;33:2553\u201361.","journal-title":"Surg Endosc"},{"key":"1773_CR53","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1007\/s00464-019-07285-w","volume":"34","author":"YQ Zhai","year":"2020","unstructured":"Zhai YQ, Chai NL, Li HK, Lu ZS, Feng XX, Zhang WG, et al. Endoscopic submucosal excavation and endoscopic full-thickness resection for gastric schwannoma: five-year experience from a large tertiary center in China. Surg Endosc. 2020;34:4943\u20139.","journal-title":"Surg Endosc"},{"key":"1773_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10147-007-0705-7","volume":"12","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12:369\u201374.","journal-title":"Int J Clin Oncol"},{"key":"1773_CR55","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1245\/s10434-018-6353-5","volume":"25","author":"T H\u00f8lmebakk","year":"2018","unstructured":"H\u00f8lmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland \u00d8S, Hall KS, et al. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol. 2018;25:1133\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR56","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1245\/s10434-019-07297-9","volume":"26","author":"T Nishida","year":"2019","unstructured":"Nishida T, H\u00f8lmebakk T, Raut CP, Rutkowski P. Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol. 2019;26:1669\u201375.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR57","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/ags3.12684","volume":"7","author":"N Gotohda","year":"2023","unstructured":"Gotohda N, Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, et al. Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2023;7:1021\u201331.","journal-title":"Ann Gastroenterol Surg"},{"key":"1773_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/SLA.0000000000003277","volume":"273","author":"MJ Cavnar","year":"2021","unstructured":"Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon SS, et al. Outcome of 1000 patients with Gastrointestinal Stromal Tumor (GIST) treated by surgery in the pre- and post-imatinib eras. Ann Surg. 2021;273:128\u201338.","journal-title":"Ann Surg"},{"key":"1773_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000452656","volume":"95","author":"N Wada","year":"2017","unstructured":"Wada N, Takahashi T, Kurokawa Y, Nakajima K, Masuzawa T, Nakatsuka R, et al. Appropriate follow-up strategies for gastrointestinal stromal tumor patients based on the analysis of recurrent interval and patterns. Digestion. 2017;95:115\u201321.","journal-title":"Digestion"},{"key":"1773_CR60","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.ejca.2015.05.009","volume":"51","author":"H Joensuu","year":"2015","unstructured":"Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Sch\u00f6ffski P, Maki RG. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. Eur J Cancer. 2015;51:1611\u20137.","journal-title":"Eur J Cancer"},{"key":"1773_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.03.025","volume":"78","author":"L D'Ambrosio","year":"2017","unstructured":"D\u2019Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, et al. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. Eur J Cancer. 2017;78:122\u201332.","journal-title":"Eur J Cancer"},{"key":"1773_CR62","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","volume":"23","author":"M Van Glabbeke","year":"2005","unstructured":"Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795\u2013804.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1773_CR63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1148\/radiol.13131040","volume":"271","author":"H Joensuu","year":"2014","unstructured":"Joensuu H, Reichardt P, Eriksson M, Sundby Hall K, Vehtari A. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. Radiology. 2014;271(1):96.","journal-title":"Radiology"},{"key":"1773_CR64","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620\u20135.","journal-title":"J Clin Oncol"},{"key":"1773_CR65","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"1773_CR66","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","volume":"120","author":"A Napolitano","year":"2019","unstructured":"Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer. 2019;120:577\u20138.","journal-title":"Br J Cancer"},{"key":"1773_CR67","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-023-02734-5","volume":"30","author":"MC Heinrich","year":"2024","unstructured":"Heinrich MC, Jones RL, George S, Gelderblom H, Sch\u00f6ffski P, von Mehren M, et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024;30:498\u2013506.","journal-title":"Nat Med"},{"key":"1773_CR68","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-23-1861","volume":"30","author":"MC Heinrich","year":"2024","unstructured":"Heinrich MC, Zhang X, Jones RL, George S, Serrano C, Deng Y, et al. Clinical benefit of Avapritinib in KIT-mutant gastrointestinal stromal tumors: a post hoc analysis of the phase I NAVIGATOR and phase I\/II CS3007-001 studies. Clin Cancer Res. 2024;30:719\u201328.","journal-title":"Clin Cancer Res"},{"issue":"4 suppl","key":"1773_CR69","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.2020.38.4_suppl.823","volume":"38","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Nishida T, Kudo T, Boku N, Honma Y, Komatsu Y, et al. Regorafenib as second-line therapy for imatinib-resistant Gastrointestinal Stromal Tumor (GIST). J Clin Oncol. 2020;38(4 suppl):823.","journal-title":"J Clin Oncol"},{"key":"1773_CR70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"1773_CR71","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:923\u201334.","journal-title":"Lancet Oncol"},{"key":"1773_CR72","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","volume":"33","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022;33:959\u201367.","journal-title":"Ann Oncol"},{"key":"1773_CR73","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1080\/14796694.2024.2376521","volume":"20","author":"S George","year":"2024","unstructured":"George S, Blay JY, Chi P, Jones RL, Serrano C, Somaiah N, et al. The INSIGHT study: a randomized, phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17\/18 mutations. Future Oncol. 2024;20:1973\u201382.","journal-title":"Future Oncol"},{"issue":"Suppl","key":"1773_CR74","doi-asserted-by":"publisher","first-page":"S1031","DOI":"10.1016\/j.annonc.2023.09.1146","volume":"34","author":"Y Naito","year":"2023","unstructured":"Naito Y, Komatsu Y, Kurokawa Y, Hirano H, Nishida T, Doi T. A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Ann Oncol. 2023;34(Suppl):S1031\u20132.","journal-title":"Ann Oncol"},{"key":"1773_CR75","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","volume":"14","author":"YK Kang","year":"2013","unstructured":"Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175\u201382.","journal-title":"Lancet Oncol"},{"key":"1773_CR76","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357\u201364.","journal-title":"J Clin Oncol"},{"key":"1773_CR77","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M, Sch\u00f6ffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21:935\u201346.","journal-title":"Lancet Oncol"},{"key":"1773_CR78","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382.","journal-title":"Lancet Oncol"},{"key":"1773_CR79","unstructured":"Loong HHF, Tinoco G, Garrido-Laguna I, Goto K, Steuer C, Liu SV, et al. Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive sarcomas. In: Connective Tissue Oncology Society (CTOS) Annual Meeting; 2022."},{"key":"1773_CR80","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"1773_CR81","unstructured":"Demetri GD, Tan DS, Bielack S, Orbach D, DuBois S, Federman NC, et al. Larotrectinib efficacy and safety in patients with TRK fusion sarcomas. In: Connective Tissue Oncology Society (CTOS) Annual Meeting; 2019."},{"key":"1773_CR82","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29:1103\u201312.","journal-title":"Nat Med"},{"key":"1773_CR83","doi-asserted-by":"publisher","first-page":"175883592110232","DOI":"10.1177\/17588359211023278","volume":"13","author":"M Nannini","year":"2021","unstructured":"Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021;13:17588359211023278.","journal-title":"Ther Adv Med Oncol"},{"key":"1773_CR84","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol. 2017;3:944\u201352.","journal-title":"JAMA Oncol"},{"key":"1773_CR85","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol. 2016;2:922\u20138.","journal-title":"JAMA Oncol"},{"key":"1773_CR86","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"E Ben-Ami","year":"2016","unstructured":"Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794\u20139.","journal-title":"Ann Oncol"},{"key":"1773_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007668","volume":"96","author":"W Liu","year":"2017","unstructured":"Liu W, Zeng X, Wu X, He J, Gao J, Shuai X, et al. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: a single-institutional experience in China. Medicine (Baltimore). 2017;96:e7668.","journal-title":"Medicine (Baltimore)"},{"key":"1773_CR88","doi-asserted-by":"crossref","unstructured":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol. 2010;28:1247\u201353.","DOI":"10.1200\/JCO.2009.24.2099"},{"key":"1773_CR89","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12029-011-9325-6","volume":"43","author":"J Hislop","year":"2012","unstructured":"Hislop J, Mowatt G, Sharma P, Fraser C, Elders A, Jenkinson D, et al. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable\/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer. 2012;43:168\u201376.","journal-title":"J Gastrointest Cancer"},{"key":"1773_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15250","volume":"15","author":"J Hislop","year":"2011","unstructured":"Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, et al. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and\/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg\/day: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013178.","journal-title":"Health Technol Assess"},{"key":"1773_CR91","doi-asserted-by":"publisher","first-page":"69412","DOI":"10.18632\/oncotarget.5136","volume":"7","author":"B Vincenzi","year":"2016","unstructured":"Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2016;7:69412\u20139.","journal-title":"Oncotarget"},{"key":"1773_CR92","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.2217\/fon-2017-0252","volume":"13","author":"Z Dong","year":"2017","unstructured":"Dong Z, Gao J, Gong J, Li J, Li Y, Shen L. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes. Future Oncol. 2017;13:2035\u201343.","journal-title":"Future Oncol"},{"key":"1773_CR93","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-21-1665","volume":"28","author":"B Vincenzi","year":"2022","unstructured":"Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay J-Y, et al. Adjuvant imatinib in patients with GIST Harboring Exon 9 KIT mutations: results from a multi-institutional European retrospective study. Clin Cancer Res. 2022;28:1672\u20139.","journal-title":"Clin Cancer Res"},{"key":"1773_CR94","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/cncr.29220","volume":"121","author":"P Reichardt","year":"2015","unstructured":"Reichardt P, Kang Y-K, Rutkowski P, Schuette J, Rosen LS, Seddon B, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015;121:1405\u201313.","journal-title":"Cancer"},{"key":"1773_CR95","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141\u20137.","journal-title":"J Clin Oncol"},{"key":"1773_CR96","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10637-013-9961-8","volume":"31","author":"C Yoo","year":"2013","unstructured":"Yoo C, Ryu MH, Ryoo BY, Beck MY, Kang YK. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg\/day in patients with advanced gastrointestinal stromal tumors. Invest New Drugs. 2013;31:1367\u201374.","journal-title":"Invest New Drugs"},{"key":"1773_CR97","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18:5780\u20137.","journal-title":"Clin Cancer Res"},{"key":"1773_CR98","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00280-014-2630-6","volume":"75","author":"DH Koo","year":"2015","unstructured":"Koo DH, Ryu MH, Ryoo BY, Beck MY, Na YS, Shin JG, et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2015;75:173\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1773_CR99","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097\u2013104.","journal-title":"Lancet"},{"key":"1773_CR100","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","volume":"33","author":"PG Casali","year":"2015","unstructured":"Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33:4276\u201383.","journal-title":"J Clin Oncol"},{"key":"1773_CR101","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.annonc.2021.01.004","volume":"32","author":"PG Casali","year":"2021","unstructured":"Casali PG, Le Cesne A, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG),\u00a0UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 2021;32:533\u201341.","journal-title":"French Sar Ann Oncol"},{"key":"1773_CR102","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Sch\u00fctte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor. JAMA. 2012;307:1265.","journal-title":"JAMA"},{"key":"1773_CR103","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jamaoncol.2020.2091","volume":"6","author":"H Joensuu","year":"2020","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Sch\u00fctte J, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors. JAMA Oncol. 2020;6:1241.","journal-title":"JAMA Oncol"},{"key":"1773_CR104","doi-asserted-by":"crossref","unstructured":"Blay JY, Schiffler C, Bouch\u00e9 O, Brahmi M, Duffaud F, Toulmonde M, et al. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol. 2024;35(12):1157\u20131168.","DOI":"10.1016\/j.annonc.2024.08.2343"},{"key":"1773_CR105","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1245\/s10434-011-2190-5","volume":"19","author":"D Wang","year":"2012","unstructured":"Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant\/adjuvant imatinib mesylate for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19:1074\u201380.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/jso.21160","volume":"99","author":"BL Eisenberg","year":"2009","unstructured":"Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665. J Surg Oncol. 2009;99:42\u20137.","journal-title":"J Surg Oncol"},{"key":"1773_CR107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/bjc.2017.144","volume":"117","author":"Y Kurokawa","year":"2017","unstructured":"Kurokawa Y, Yang H-K, Cho H, Ryu M-H, Masuzawa T, Park SR, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer. 2017;117:25\u201332.","journal-title":"Br J Cancer"},{"key":"1773_CR108","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejso.2012.09.004","volume":"39","author":"R Tielen","year":"2013","unstructured":"Tielen R, Verhoef C, Van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol. 2013;39:150\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"1773_CR109","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1245\/s10434-008-0177-7","volume":"16","author":"JC Mcauliffe","year":"2009","unstructured":"Mcauliffe JC, Hunt KK, Lazar AJF, Choi H, Qiao W, Thall P, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR110","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","volume":"20","author":"P Rutkowski","year":"2013","unstructured":"Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Sch\u00f6ffski P, Bauer S, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937\u201343.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR111","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10147-007-0746-y","volume":"13","author":"T Nishida","year":"2008","unstructured":"Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol. 2008;13:244\u201351.","journal-title":"Int J Clin Oncol"},{"key":"1773_CR112","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","volume":"24","author":"CP Raut","year":"2006","unstructured":"Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325\u201331.","journal-title":"J Clin Oncol"},{"key":"1773_CR113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jso.21065","volume":"98","author":"SJ Sym","year":"2008","unstructured":"Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98:27\u201333.","journal-title":"J Surg Oncol"},{"key":"1773_CR114","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/SLA.0000000000002281","volume":"268","author":"M Fairweather","year":"2018","unstructured":"Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, et al. Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors. Ann Surg. 2018;268:296\u2013302.","journal-title":"Ann Surg"},{"key":"1773_CR115","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1245\/s10434-014-3866-4","volume":"21","author":"SJ Park","year":"2014","unstructured":"Park SJ, Ryu M-H, Ryoo B-Y, Park YS, Sohn BS, Kim HJ, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol. 2014;21:4211\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1773_CR116","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","volume":"40","author":"S Bauer","year":"2014","unstructured":"Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"1773_CR117","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ejca.2014.03.280","volume":"50","author":"CY Du","year":"2014","unstructured":"Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014;50:1772\u20138.","journal-title":"Eur J Cancer"},{"key":"1773_CR118","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/jso.21630","volume":"102","author":"CN Yeh","year":"2010","unstructured":"Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010;102:599\u2013603.","journal-title":"J Surg Oncol"},{"key":"1773_CR119","doi-asserted-by":"publisher","first-page":"e1443","DOI":"10.1634\/theoncologist.2019-0009","volume":"24","author":"H Cho","year":"2019","unstructured":"Cho H, Ryu MH, Lee Y, Park YS, Kim KH, Kim JH, et al. Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumors: results of propensity score analyses. Oncologist. 2019;24:e1443\u20139.","journal-title":"Oncologist"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01773-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:02:40Z","timestamp":1787900560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01773-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01773-4","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H.\n                      has received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Novartis, Daiichi-Sankyo and Taiho Pharmaceutical and has received grants from PPD, Daiichi-Sankyo, Nippon Boehringer Ingelheim, ALX Oncology, BeiGene, Novartis, Amgen, Bristol-Myers Squibb, Seagen, and Taiho Pharmaceutical.\n                      Y.N\n                      has received honoraria from AstraZeneca, Eisai, Ono, Guardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, PDR Pharma, Nihon Kayaku, Taiho, Bristol, Bayer, Daiichi Sankyo, MSD, and Gilead and has received grants from ABBVIE, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, Bayer, Takeda, Anthos Therapeutics, and Gilead and has received consulting fees from AstraZeneca, Eisai, Gilead, Eli Lilly, Novartis, Pfizer, Chugai, Taiho, Bayer, and Daiichi Sankyo.\n                      T.T\n                      has received honoraria from Nippon Kayaku Co., Ltd., Tsumura & Co., and TAIHO PHARMACEUTICAL, CO., LTD.\n                      M.H.R\n                      has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, DAEHWA Pharmaceutical, Daiichi Sankyo, Lilly, MSD, Novartis, Ono Pharmaceutical, and Taiho Pharmaceutical, and has received consulting fees from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, DAEHWA Pharmaceutical, Daiichi Sankyo, Lilly, MSD, Novartis, Ono Pharmaceutical, and Taiho Pharmaceutical, and has received grants from AstraZeneca, Bristol-Myers Squibb and Ono Pharmaceutical.\n                      C.C.Y\n                      has received grants from Deciphera, BioAtla, Boehringer Ingelheim, Cogent Biosciences, Polaris, Taiho, PharmaEssentia, GSK, Napo Pharmaceuticals, and Rain Therapeutics and has participated on a data safety monitoring board or advisory board for Daiichi Sankyo and FullHope Biomedical. L.T.C has received honoraria from Novartis, CStone and ACTgenomics, and has grants from ACT Genomics, Pfizer, Novartis, and Taiho, and has received consulting fees from Academab Biomedical Inc, and has participated on a data safety monitoring board or advisory board for ONO PHARMACEUTICAL, AstraZeneca, Astellas, TTY and MSD.\n                      T.N\n                      has received honoraria from Pfizer, Taiho Pharma and Eisai, and has received consulting fees from Taiho Pharma.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}